These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

558 related articles for article (PubMed ID: 19337533)

  • 21. Cilostazol: treatment of intermittent claudication.
    Reilly MP; Mohler ER
    Ann Pharmacother; 2001 Jan; 35(1):48-56. PubMed ID: 11197586
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cilostazol: a review of its use in intermittent claudication.
    Chapman TM; Goa KL
    Am J Cardiovasc Drugs; 2003; 3(2):117-38. PubMed ID: 14727939
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of intermittent claudication with pentoxifylline and cilostazol.
    Tjon JA; Riemann LE
    Am J Health Syst Pharm; 2001 Mar; 58(6):485-93; quiz 494-6. PubMed ID: 11286146
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacotherapy for peripheral arterial disease: emerging therapeutic options.
    Jaff MR
    Angiology; 2002; 53(6):627-33. PubMed ID: 12463615
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial.
    Beebe HG; Dawson DL; Cutler BS; Herd JA; Strandness DE; Bortey EB; Forbes WP
    Arch Intern Med; 1999 Sep; 159(17):2041-50. PubMed ID: 10510990
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of cilostazol in the treatment of intermittent claudication.
    Barnett AH; Bradbury AW; Brittenden J; Crichton B; Donnelly R; Homer-Vanniasinkam S; Mikhailidis DP; Stansby G
    Curr Med Res Opin; 2004 Oct; 20(10):1661-70. PubMed ID: 15462700
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacological treatment of intermittent claudication does not have a significant effect on gait impairments during claudication pain.
    Yentes JM; Huisinga JM; Myers SA; Pipinos II; Johanning JM; Stergiou N
    J Appl Biomech; 2012 May; 28(2):184-91. PubMed ID: 22723116
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Type 3 phosphodiesterase inhibitors may be protective against cerebrovascular events in patients with claudication.
    Stone WM; Demaerschalk BM; Fowl RJ; Money SR
    J Stroke Cerebrovasc Dis; 2008; 17(3):129-33. PubMed ID: 18436153
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The limits of evidence in drug approval and availability: a case study of cilostazol and naftidrofuryl for the treatment of intermittent claudication.
    Hong H; Mackey WC
    Clin Ther; 2014 Aug; 36(8):1290-301. PubMed ID: 25012728
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Cilostazol improves the quality of life and lower-limb functional capacity also in diabetic patients].
    Farkas K; Kolossváry E; Járai Z
    Orv Hetil; 2020 Sep; 161(38):1637-1645. PubMed ID: 32924968
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of intermittent claudication: cilostazol.
    Collins P; Brittenden J
    Hosp Med; 2004 Aug; 65(8):466-70. PubMed ID: 15330347
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of cilostazol, a novel phosphodiesterase inhibitor in patients with intermittent claudication.
    Samra SS; Bajaj P; Vijayaraghavan KS; Potdar NP; Vyas D; Devani RG; Ballary C; Desai A
    J Indian Med Assoc; 2003 Sep; 101(9):561-2, 564. PubMed ID: 15168999
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Cilostazol is effective and safe option for the treatment of intermittent claudication. Results of the NOCLAUD study].
    Farkas K; Járai Z; Kolossváry E
    Orv Hetil; 2017 Jan; 158(4):123-128. PubMed ID: 28116935
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Medical management of peripheral arterial disease.
    Creager MA
    Cardiol Rev; 2001; 9(4):238-45. PubMed ID: 11405904
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of cilostazol prescribed in a pragmatic treatment program for intermittent claudication.
    Lee C; Nelson PR
    Vasc Endovascular Surg; 2014 Apr; 48(3):224-9. PubMed ID: 24399131
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment with pharmacological agents in peripheral arterial disease patients does not result in biomechanical gait changes.
    Huisinga JM; Pipinos II; Stergiou N; Johanning JM
    J Appl Biomech; 2010 Aug; 26(3):341-8. PubMed ID: 20841626
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cilostazol: new drug. Intermittent claudication: too little efficacy, too many risks.
    Prescrire Int; 2009 Apr; 18(100):56-9. PubMed ID: 19585717
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative effects of cilostazol and other therapies for intermittent claudication.
    Dawson DL
    Am J Cardiol; 2001 Jun; 87(12A):19D-27D. PubMed ID: 11434896
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapeutic Effects of Medication Use on Intermittent Claudication: A Network Meta-analysis.
    Ma B; Fan X; Liu P
    J Cardiovasc Pharmacol; 2021 Feb; 77(2):253-262. PubMed ID: 33235027
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Simple assessment of quality of life and lower limb functional capacity during cilostazol treatment - results of the SHort-tERm cIlostazol eFFicacy and quality of life (SHERIFF) study.
    Farkas K; Kolossváry E; Járai Z
    Vasa; 2020 Apr; 49(3):235-242. PubMed ID: 31983287
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.